Kornimate/medical-research-clean huggingface dataset:
prognostic significance of red blood cell

Conditions: Critical Illness

Summary: red blood cell (rbc) distribution width (rdw), calculated by dividing the standard deviation of rbc volume by the mean corpuscular volume and multiplied by 100, is routinely reported as part of the complete blood count (cbc) using automated flow cytometry. rdw has been traditionally used as additional information in the differential diagnosis of the cause of anemia. rdw has been recently reported as a strong prognostic factor in several diseases of various organ systems, including the cardiovascular, respiratory, renal, neurologic, and gastrointestinal systems.it also showed significant associations with ventilator-free days, postoperative outcome, intensive care unit (icu) discharge outcome, out-of-hospital outcome, and all-cause mortality in critically ill patients. however, most studies were conducted in adult patients. only a few studies have investigated rdw in children, especially in the critically ill pediatric population.

the aim of this study is to know the prognostic significance of red blood cell distribution width ( rdw ) in critically ill pediatric patients as regard ; the duration of hospital \& picu admission ,the use of inotropic drugs and or mechanical ventilation (mv) and the outcome of the case .

Eligibility criteria:
inclusion criteria: * all critically ill pediatric patients, 1 month to 12 years age, admitted to pediatric intermediate \& intensive care unit ( picu ) in sohag university hospital. exclusion criteria: * - patients who received blood transfusion prior to admission in picu * patients with incomplete data for pediatric risk of mortality (prism), pediatric sequential organ failure assessment (psofa), pediatric logistic organ dysfunction-2 (pelod-2), and pediatric multiple organ dysfunction syndrome (pmods) scores were excluded.
mechanisms of hypoglycemia associated autonomic dysfunction question 2

Conditions: Type 1 Diabetes

Summary: the purpose of this study is to determine the way by which alprazolam (xanax) an anti-anxiety drug affects specialized molecules in your brain called gaba (a) receptors that alter your body's ability to defend itself from low blood sugar (hypoglycemia). we hypothesize that prior activation of gaba (a) receptors may result in blunting of counterregulatory responses during subsequent hypoglycemia and exercise.

the ultimate goal of this project is to identify treatments and approaches that will allow patients with diabetes to enjoy all the benefits of good glycemic control without the damaging limitations of severe hypoglycemia. the specific aim of this study is to determine if gamma aminobutyric acid (gaba a) receptors plays a role in the development of exercise associated autonomic dysfunction in type 1 diabetes and healthy man.

Eligibility criteria:
inclusion * 14 type 1 dm patients (7 male and 7 female) aged 18-50 years * hba1c \> 6% * bmi\<35 kg/m2 * 14 healthy individuals (7 male and 7 female) aged 18-50 years, bmi matched exclusion * pregnant women * subjects unable to give voluntary informed consent * subjects on anticoagulant drugs, anemic or with known bleeding diatheses * subjects taking any of the following medications will be excluded: non-selective beta blockers, sedative-hypnotics, anticonvulsants, antiparkinsonian drugs, antipsychotics, antidepressants, mood stabilizers, cns stimulants, opioids, hallucinogens * subjects with a recent medical illness * subjects with a history of hypertension, heart disease, cerebrovascular incidents * subjects with known liver or kidney disease physical exam exclusion criteria * history of uncontrolled severe hypertension (i.e., blood pressure greater than 150/95) * clinically significant cardiac abnormalities (e.g. heart failure, arrhythmia) * pneumonia * hepatic failure /jaundice * renal failure * acute cerebrovascular/ neurological deficit * fever greater than 38.0 c screening laboratory blood tests exclusion criteria according to protocol

Keywords: type 1 diabetes alprazolam exercise
am vs pm exercise training

Conditions: Hypertension

Summary: the treatment of high blood pressure, or hypertension, is multifaceted and can include pharmacological therapies (i.e., medications) and lifestyle modifications such as physical activity. chronotherapy, which describes timing of a treatment with the body's daily rhythms, has recently been used with hypertension medications and has been shown to be effective at lowering blood pressure and reducing the risk of cardiovascular disease events. specifically, taking medications in the evening was shown to be more effective than morning medication routines. little information is available about the effectiveness of chronotherapy combined with exercise (i.e., planned physical activity) interventions in older adults with hypertension. the purpose of this study is to examine how exercise training performed in the morning and early evening affects blood pressure and other measures of blood vessel health in postmenopausal females with hypertension.

blood pressure has an internal rhythm associated with the 24-hr clock. nocturnal blood pressure (bp) is a key contributor to cardiovascular health and may be improved by exercise. moreover, the time of day of the exercise may be a key factor. this study aims to evaluate the effects of morning and evening exercise training on bp and other measures of vascular function in older females with hypertension.

Eligibility criteria:
inclusion criteria: * systolic bp equal to or greater than 130 mmhg without bp medication or greater than 120 mmhg with medication and diastolic blood pressure equal to and greater than 80 mmhg * 55-80 years old * post-menopausal female * able to walk without assistance exclusion criteria: * habitually physically active defined as 150 minutes of moderate-intensity or 75 minutes of vigorous-intensity aerobic physical activity per week * overt pulmonary disease/condition as follows: chronic bronchitis, chronic obstructive pulmonary disease, emphysema, or pulmonary hypertension * cardiometabolic disease/condition as follows: diabetes, heart failure, peripheral arterial disease, stroke, coronary artery disease, renal disease, secondary hypertension, chronic venous insufficiency or deep vein thrombosis within last 6 months * cancer within last 5 years * body mass index \>39 kg/m2 * current smoking or vape * evening shift work * uncontrolled thyroid disorder * 2 or more falls in the last year * anemia within 3 months of enrollment * parkinson's disease * dementia * unstable angina * acute pulmonary embolus or infarction * acute myocarditis or pericarditis * acute aortic dissection
safety and efficacy pilot study of azasite® for four weeks in subjects with blepharitis

Conditions: Blepharitis

Summary: the purpose of this study is to evaluate the safety and efficacy of azasite® ophthalmic solution, 1% on signs and symptoms of blepharitis.


Eligibility criteria:
inclusion criteria: * diagnosis of moderate to severe chronic posterior blepharitis * if female of childbearing potential, are non-pregnant and non-lactating exclusion criteria: * had ocular surface surgery (lasik, refractive, pterygium) within the past year * unwilling to discontinue use of contact lenses during the study * have glaucoma * unable or unwilling to withhold the use of eyelid scrubs during the study * have a serious systemic disease or uncontrolled medical condition that in the judgment of the investigator could confound study assessments or limit compliance * currently using any preserved topical ocular medications (with the exception of unpreserved tear substitutes) at the time of entry into the study or during study participation
systematic review: retigabine for adjunctive therapy in partial epilepsy

Conditions: Epilepsy

Summary: there are a number of anti-epileptic drugs available for the treatment of partial onset seizures in patients with epilepsy. this study is a systematic review of the published literature on anti-epileptic drugs and is designed to compare the relative effectiveness and tolerability of a selection of them with retigabine. the drugs chosen for this comparison were lacosamide, pregabalin, tiagabine, zonisamide and eslicarbazepine. they were chosen because they belong to the newer generation of drugs for epilepsy (as does retigabine) and they have a similar license as well as having published data from studies that were conducted in similar patient populations with similar methods. gsk commissioned yhec (york health economic consortium) to carry out this review and analysis. yhec identified relevant studies from international databases. these studies had compared one of the chosen anti-epileptic drugs with placebo. the results were pooled and combined in order to summarize the data for individual drugs as well to compare the results for different drugs with each other and with retigabine. since none of the individual clinical studies compared one active drug with another, this systematic review is an indirect comparison of these drugs, using an established and recognised methodology which has well understood limitations.


Eligibility criteria:
inclusion criteria: * have participated to a study that meets the following criteria: * be a study of retigabine, eslicarbazepine, lacosamide, zonisamide, pregabalin or tiagabine as an adjuvant therapy, compared to placebo or another drug; * be a randomized, placebo-controlled, add-on trial, or a parallel trial or cross-over trial in which data from the first treatment period could be treated as a parallel study; * have recruited patients with drug-resistant partial epilepsy (i.e., simple partial, complex partial, and/or secondarily generalised tonic-clonic seizures not controlled by at least 1 or more other aeds); * have a maintenance treatment period of 8 weeks or longer, with a prospective baseline of minimum 4 weeks. exclusion criteria: * n/a
investigation of corneal aberrations and visual outcomes in patients implanted with an acrysof toric intraocular lens (iol)

Conditions: Cataracts; Astigmatism

Summary: a prospective evaluation of postoperative corneal aberrations and visual parameters (e.g. visual acuity) in patients implanted with an acrysof toric iol.


Eligibility criteria:
inclusion criteria: * operable cataracts; * good ocular health; * qualifies for acrysof toric iol via acrysof toric calculator (1.03-2.06 d cylinder at corneal plane) exclusion criteria: * \>2.06 d astigmatism at corneal plane; * irregular astigmatism; * prior or ongoing corneal disease or scarring; * history of ocular disease

Keywords: cataract toric iol corneal aberration astigmatism acrysof
characteristics of signal intensity gradient in subarachnoid hemorrhage after aneurysmal rupture

Conditions: Aneurysmal Rupture

Summary: 10-20% of patients with subarachnoid hemorrhage die before they arrive at the hospital, and about 25% die within 24 hours. about 1% of patients are diagnosed with cerebral aneurysms in imaging tests for health checkups, and many of them experience aneurysmal rupture during their lifetime, so it is not a rare disease. wall shear stress is known to be a factor that reflects the state of blood vessels, and particularly plays an important role in the patency of the intima of blood vessels. in the meantime, computed fluid dynamics (cfd), a representative method for calculating wall shear stress, assumes a virtual rigid pipe and applies a preset value. this does not accurately reflect the physiological and dynamic state of the actual blood vessel. the investigators intend to measure the patient's wall shear stress using the sig of the mra-tof technique, which reflects the physiological characteristics of individual patients, and to analyze the association with rupture of the intracranial aneurysm.


Eligibility criteria:
\ inclusion criteria: 1) patients over 18 years of age who visited our hospital for acute subarachnoid hemorrhage due to rupture of a intracranial aneurysm (2) among patients satisfying (1), who had intracranial magnetic resonance imaging (time-of-flight (tof) technique applied; diffusion-weighted imaging, including apparent diffusion coefficient) before subarachnoid hemorrhage occurred. exclusion criteria: 1. patients under the age of 18 2. patients with subarachnoid hemorrhage due to causes other than rupture of intracranial aneurysm 3. patients with poor imaging quality due to artifacts caused by patient movement during brain magnetic resonance imaging examination \ inclusion criteria: 1. magnetic resonance imaging performed during the screening period (time-of-flight (tof) technique is applied to intracranial vessel imaging; it also includes diffusion-weighted imaging and apparent diffusion coefficient) 2. patients diagnosed with unruptured intracranial aneurysm in the final reading of brain mr test 3. patients who remain without aneurysmal rupture on follow-up intracranial magnetic resonance imaging exclusion criteria: 1. patients under the age of 18 2. patients with poor imaging quality due to artifacts caused by patient movement during brain magnetic resonance imaging examination

Keywords: signal intensity gradient wall shear stress aneurysmal rupture time-of-flight mri
3d body surface modeling for scoliosis monitoring

Conditions: Adolescent Idiopathic Scoliosis

Summary: this is a single center, prospective, non-randomized reproducibility study of the nsite device in patients undergoing evaluation for scoliosis. the nsite device is a pre-market, investigational device. the study will enroll 13 eligible patients, who will be scanned using the nsite device by 3 separate users in order to assess if the device generates similar results across users. this data will be used to support 510(k) submission.

the primary objective of this study is to validate the reproducibility of device output in multiple users in a clinical setting. device output will be predicted probability of major curve magnitude (i.e., cobb angle) greater than or equal to 20 degrees with 95% confidence interval. we will test whether users obtain similar device output when measuring the same participant (at least 2 scans required for analysis). after excluding bad quality scans, the measurements obtained by these different users (at least 2 users after excluding bad scans) on each study participant will then be compared to determine if they are congruent (having overlapping confidence intervals) or different. the percentage of participants for which users generated congruent predicted probabilities will be reported. the nsite scoliosis assessment app is intended as a clinical decision support tool and requires interpretation by the healthcare professional. it is intended for use for children and adolescent patients 10 to 18 years old. it is for use by prescription only. the nsite scoliosis assessment app provides a calculated asymmetry index for patients with or at risk for scoliosis, which will yield an output of percentage risk of major curve magnitude (i.e., cobb angle) greater than 20 degrees, with 95% confidence intervals.

Eligibility criteria:
inclusion criteria: * ages 10 and 18 years old * referred for evaluation of or diagnosed of adolescent idiopathic scoliosis exclusion criteria: * scoliosis caused by another condition (e.g., secondary scoliosis) * parents/guardians unable to consent * english is not the primary language (to avoid miscommunication)
spinal curvature, mobility, and low back pain relationship in women with and without urinary incontinence

Conditions: Urinary Incontinence

Summary: the aim of this study was to investigate the relationship among sagittal spinal curvatures, mobility, and low back pain in women with and without urinary incontinence.


Eligibility criteria:
inclusion criteria: * aged between 20 and 65 years, * diagnosed with stress and mixed urinary incontinence * healthy women exclusion criteria: * women with prior history of injury or surgery related to spine, * spinal deformity, * systemic pathology, * any rheumatologic disease, * neurologic condition, * symptomatic pelvic organ prolapse, * malignancy, * pregnancy
assessment of the pharmacokinetics of blu-5937 extended release prototypes and a blu-5937 immediate release reference formulation

Conditions: Cough; Healthy

Summary: this is a phase 1, single-centre, open-label, two-part, sequential cross-over study designed to assess the pharmacokinetic profile of blu-5937 following administration of extended release formulation prototypes and an immediate release reference formulation in healthy male and female subjects


Eligibility criteria:
inclusion criteria: * healthy males or non-pregnant, non-lactating healthy females exclusion criteria: * history of clinically significant cardiovascular, renal, hepatic, metabolic, dermatological, respiratory, gi, neurological, endocrine, haematological, immunological or psychiatric disorder, as judged by the investigator.
next generation sequencing of tumor cells in locally advanced pancreatic adenocarcinoma

Conditions: Adenocarcinoma

Summary: all patients referring to the u.o .of digestive endoscopy of the humanitas hospital to undergo eus with biopsy in the pre-treatment evaluation of locally advanced pancreatic adenocarcinoma, satisfying all the inclusion criteria and without any of the exclusion criteria, will be enrolled. patients will then undergo endoscopic procedures (eus with biopsy) provided by good clinical practice in consideration of the suspected diagnosis for which they come to investigator's attention. biopsy will be performed using a histology needle (22 g, acquire, boston scientific, ma, united states). the obtained material will be processed in the pathological anatomy. a small part of this will be sent to the ngs analysis. at the time of preparation for the examination, the patients will be asked for blood collection (10 ml of blood) in order to evaluate any circulating tumor cells that will be identified by smartbiosurface technique (tethis s.p.a) and analyzed by appropriate molecular markers and ngs. the clinical evaluation of the patient will take place at 6 months from the date of the procedure, through telephone contact and / or outpatient visit.


Eligibility criteria:
inclusion criteria: * age\> 18 years, * signature of informed consent, * naïve patients with pancreatic adenocarcinoma (confirmed cito/ histologically), not subjected to previous treatments, * need to perform eus with biopsy, * life expectancy over 6 months. exclusion criteria: * patients with non-primary pancreatic tumors, pancreatic neuroendocrine tumors or benign pancreatic masses * patients who have already undergone cancer treatment of any kind
transcranial direct current simulation in chronic migraine

Conditions: Migraine Disorders

Summary: this study is a pilot, double-blind, placebo-controlled, randomized trial aiming to compare the effects of transcranial direct current stimulation in chronic migraine.

the patients will be randomized into 1 of 3 groups: active tdcs over primary motor cortex, active tdcs over prefrontal cortex, sham tdcs. each group will receive treatment for 20 minutes a day, 3 days a week for 4 weeks.

Eligibility criteria:
inclusion criteria: * patients with a clinical diagnosis of chronic migraine according to the international classification of headaches disorders (ichd-3 beta) of the international headache society, with an established headache history occurring on 15 or more days per month-however, for at least 1 year, instead of only 3 months, as defined in the international headache society (ihs) guidelines. exclusion criteria: * headache attributable to some pathological condition, associated neurologic or neuropsychiatric disease, use of central nervous system modulating drugs, pregnancy, metallic head implants, and use of a cardiac pacemaker.
effect of cilostazol on endothelial progenitor cells and endothelial function in coronary artery disease

Conditions: Coronary Artery Disease

Summary: 1. the number and function of circulating endothelial progenitor cells (epcs) are inversely associated with coronary risk factors and atherosclerotic diseases such as coronary artery disease (cad) and cardiovascular high risk. 2. this double-blind, randomized, placebo-controlled trial to evaluate the effects of cilostazol on human early epcs and endothelial function as well as the potential mechanisms of action in patients with cad and cardiovascular high risk.

1. titration of drugs 1. run-in period: eligible subjects are screened and baseline blood samples are obtained 2. study period: 12 weeks * subjects with cilostazol and subjects with dummy placebo * on the first day after the end of the study period, the follow-up data are obtained by the same procedure 3. blood sampling and measurement of serum biomarkers * obtained from peripheral veins in all study subjects at the run-in period and the end of the treatment period of the study * sent for isolation, cell culture, and assays of human epcs * also stored for enzyme-linked immunosorbent assay (stromal cell derived factor-alfa1, adiponectin, soluble thrombomodulin, vascular endothelial growth factor) 2. assays of human epcs 1. colony formation by epcs 2. quantification of epcs and apoptotic endothelial cells 3. chemotactic motility, proliferation/viability and apoptosis assays 3. measurement of flow-mediated dilatation (fmd) of left brachial artery by sonography 4. assessment of long-term cardiovascular outcomes

Eligibility criteria:
inclusion criteria: * stable cad documented by stress test, computed tomography angiography or coronary angiography or * old myocardial infarction (\>6 months) * history and evidence of cad * history and evidence of cerebrovascular accident * history and evidence of peripheral artery disease * diabetes mellitus * metabolic syndrome * stage 3 to 5 chronic kidney disease * at least 2 of the followings: male ≥45 years old or female ≥55 years old; hypertension; current or past 3-year tobacco smoking; hyperlipidemia; family history of premature cad (male \<55 years old or female \<65 years old) exclusion criteria: * unstable cad * have plan to do percutaneous intervention or bypass surgery for cad or peripheral artery disease within recent 3 months * severe liver dysfunction (transaminases \>10 times of upper normal limit, history of liver cirrhosis, or hepatoma) * left ventricular ejection fraction (\<50% by echocardiography) * documented active malignancy * chronic inflammatory disease * known drug allergy history for cilostazol * current use of cilostazol or any other camp-elevator * premenopausal women

Keywords: cilostazol progenitor cells coronary artery disease myocardial infarction angiogenesis biological markers endothelial function